NNVC Stock UPDATES Nanoviricides Inc (NNVC) 3.67 09/09/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Nanoviricides Inc (NNVC) 3.67 $NNVC

Global Ebola and Marburg Infections Therapeutics Pipeline Report 2014 - 10 Companies & 12 Drug Profiles
M2 - Tue Sep 09, 9:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gjrkc2/ebola_and_marburg) has announced the addition of the "Ebola and Marburg Infections - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Ebola and Marburg Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ebola and Marburg Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - GlaxoSmithKline plc - Inovio Pharmaceuticals, Inc. - Bavarian Nordic A/S - Crucell N.V. - NanoViricides, Inc. - AlphaVax, Inc. - Immunovaccine, Inc. - Integrated BioTherapeutics, Inc. - Profectus BioSciences, Inc. - Mapp Biopharmaceutical, Inc. Drug Profiles - Vaccine for Multivalent Filovirus - Ebola Vaccine Marburg Vaccine - Vaccine For Filovirus - Ebola/Marburg Program - Ebola And Marburg Vaccine - Monoclonal Antibody for Marburg Virus - Polyvalent DNA Vaccine for Ebola and Marburg Filoviruses - MVA-BN-Filoviruses Vaccine - rVSV-Vectored Vaccines - Subunit Vaccine for Multifiloviruses - Monoclonal Antibodies to Inhibit Glycoprotein for Marburg Virus Infection - Monoclonal Antibodies for Ebola and Marburg Infections For more information visit http://www.researchandmarkets.com/research/gj...nd_marburg

NanoViricides receives USD7.5m upon exercise of certain old warrants
M2 - Tue Sep 09, 6:47AM CDT
Nanomaterials viral therapy company NanoViricides (NYSE MKT:NNVC) announced on Monday that it has received about USD7.48m from the exercise of certain old warrants by its existing warrant holders.

NanoViricides Reports That It Has Designed and Commenced Synthesis of Novel Ebola Drug Candidates; Dr. Seymour To Present At The Rodman And Renshaw Conference In New York Today
Business Wire - Tue Sep 09, 6:00AM CDT
NanoViricides, Inc. (NYSE MKT:NNVC) (the "Company" , a nanomedicine company developing anti-viral drugs, reported further progress in its anti-Ebola drug development program. The Company has designed novel anti-Ebola broad-spectrum drug candidates that are expected to continue to work in spite of mutations, and has commenced synthesis of the same.

NanoViricides Raises Approximately $7.5 Million Upon Exercise of Certain Old Warrants by Its Long Standing Investors
Business Wire - Mon Sep 08, 6:00AM CDT
NanoViricides, Inc. (NYSE MKT:NNVC) (the "Company" reported today that it has raised approximately $7.48 Million dollars due to the exercise of certain old warrants (see below) by its existing warrant holders.

SeeThruEquity Issues Update Note on NanoViricides Highlighting FluCide(tm) Program Update and Restart of its Ebola Drug Development Program
ACCESSWIRE - Tue Aug 19, 7:34AM CDT
NanoViricides rang the The Opening Bell at the New York Stock Exchange on August 13, 2014 to celebrate its new cGMP manufacturing capability that enables the company to move its drug development programs such as the one of Ebola into the clinic rapidly

NanoViricides to Ring Opening Bell at New York Stock Exchange
Business Wire - Tue Aug 12, 5:40PM CDT
NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company" , a nanomedicines company developing drugs that viruses would not readily escape, will ring The Opening Bell(R) at the New York Stock Exchange (NYSE) on Wednesday, August 13, 2014, tomorrow. NanoViricides began trading on NYSE MKT as of September 25, 2013.

Potential Payoffs Spur Big Board Biotech Action
ACCESSWIRE - Tue Aug 12, 2:03PM CDT
Los Angeles, CA / ACCESSWIRE / August 12, 2014 / Speculators were pushing certain big board biotechs higher as they placed their bets on potentially big future payoffs.

Traders Get Bullish on Shares of NanoViricides , Shares Up 8.5% (NNVC)
Comtex SmarTrend(R) - Fri Aug 08, 11:37AM CDT
NanoViricides (NASDAQ:NNVC) is one of today's best performing low-priced stocks, up 8.5% to $4.34 on 1.3x average daily volume. NanoViricides has traded 460,000 shares thus far today, vs. average volume of 364,000 shares per day. The stock has outperformed the Dow (8.5% to the Dow's 0.4%) and outperformed the S&P 500 (8.5% to the S&P's 0.4%) during today's trading.

NanoViricides Up 5.3%, Shares Break Through Resistance (NNVC)
Comtex SmarTrend(R) - Mon Aug 04, 11:38AM CDT
NanoViricides (NASDAQ:NNVC) is one of today's best performing low-priced stocks, up 5.3% to $4.38 on 2.2x average daily volume. Thus far today, NanoViricides has traded 735,000 shares, vs. average volume of 333,000 shares per day. The stock has outperformed the Dow (5.3% to the Dow's 0.1%) and outperformed the S&P 500 (5.3% to the S&P's 0.2%) during today's trading.

NanoViricides to re launch its Anti-Ebola Virus drug development programme
M2 - Mon Aug 04, 7:01AM CDT
Viral therapy company NanoViricides (NYSE MKT:NNVC) said on Monday that it is now starting its NV-INF-1 drug development programme to combat Ebola virus infections, a deadly disease, with 60% to 90% of infected people dying, depending upon the strain of the virus.

NanoViricides to Restart its Anti-Ebola Virus Drug Development Program
Business Wire - Mon Aug 04, 6:00AM CDT
NanoViricides, Inc. (NYSE MKT:NNVC) (the "Company" reports that it is restarting its drug development program to combat Ebola virus infections.

NanoViricides President Dr. Diwan was an Invited Participant at the Prestigious CEO Roundtable
Business Wire - Wed Jul 23, 6:00AM CDT
NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company" reports that its President, Dr. Anil Diwan, was invited to participate in the 29th Annual Chief Executive of the Year Gala Reception & Dinner held at the New York Stock Exchange on Thursday, July 17, 2014. In addition, he was also invited to participate in the CEO Roundtable Discussion, on the topic of "Enhancing CEO Effectiveness by Redefining the Role of the CFO", which was held prior to the Reception, from 4pm to 5:50pm.

NanoViricides opens new R&D and cGMP Pilot Manufacturing Facility in Connecticut
M2 - Wed Jul 23, 3:07AM CDT
NanoViricides Inc (NYSE MKT:NNVC) on Tuesday announced the opening of its new R&D and cGMP pilot manufacturing facility in Connecticut on 21 July 2014.

NanoViricides Inc. Celebrated the Grand Opening of Its New R&D and cGMP Pilot Manufacturing Facility with Congressman Jim Himes as the Chief Guest Yesterday
Business Wire - Tue Jul 22, 6:01AM CDT
NanoViricides, Inc. (NYSE MKT:NNVC) (the "Company" celebrated the grand opening of its new R&D and cGMP pilot manufacturing facility with Congressman Jim Himes as the Chief Guest yesterday, July 21. In addition, Senator Chris Murphy and Senator Richard Blumenthal sent delegates on their behalf while CT Governor Malloy sent a congratulatory Proclamation and was represented by Cowlis Andrews from CT's Office of Business Development of the Department of Economic and Community Development (DECD).

H5N1 Infection (Avian Influenza) - Pipeline Review, H1 2014
M2 - Tue Jul 15, 11:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/748t6b/h5n1_infection) has announced the addition of the "H5N1 Infection (Avian Influenza) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for H5N1 Infection (Avian Influenza), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for H5N1 Infection (Avian Influenza) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of H5N1 Infection (Avian Influenza) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for H5N1 Infection (Avian Influenza) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the H5N1 Infection (Avian Influenza) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the H5N1 Infection (Avian Influenza) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - Johnson & Johnson - Autoimmune Technologies, LLC - GlaxoSmithKline plc - Inovio Pharmaceuticals, Inc. - Daiichi Sankyo Company, Limited - Emergent BioSolutions Inc. - Generex Biotechnology Corporation - Takeda Pharmaceutical Company Limited - Nanotherapeutics, Inc. - Novartis AG - CEL-SCI Corporation - OPKO Health, Inc. - Hemispherx Biopharma, Inc. - Medicago Inc. - BioDiem Ltd - NanoViricides, Inc. - Medigen Biotechnology Corporation - SIGA Technologies, Inc. - XOMA Corporation - Green Cross Corporation - Antigen Express, Inc. - Adimmune Corporation - TechnoVax, Inc. - Cocrystal Pharma, Inc. - PaxVax - Vivaldi Biosciences Inc. - Aprogen, Inc. - Akshaya Bio Inc. - Gemmus Pharma Inc. For more information visit http://www.researchandmarkets.com/research/74..._infection

NanoViricides President Dr. Diwan Presented FluCide Data at the 3rd Annual Influenza Conference held by GTC Bio on Friday, July 11
Business Wire - Mon Jul 14, 7:01AM CDT
NanoViricides, Inc. (NYSE MKT:NNVC) (the "Company" reports that its President, Dr. Anil Diwan, was invited to present the FluCide(TM) data at the 3rd Annual Influenza Research and Development Conference on Friday, July 11, at 0850 am. The Conference ran from July 9-11 at the Hyatt Regency in Boston, MA, and was held by GTC Bio (https://www.gtcbio.com/conferences/influenza-research-and-development-agenda).

NanoViricides Reports that its Director Dr. Milton Boniuk, a Director, Has Invested $5M into the Company in a Convertible Debenture
Business Wire - Wed Jul 02, 6:00AM CDT
NanoViricides, Inc. (NYSE MKT:NNVC) (the "Company" reported today that Milton Boniuk, MD, the Caroline F. Elles Chair Professor of Ophthalmology at Baylor College of Medicine, and a Director of the Company, has invested $5M in the Company in the form of a convertible debenture (the "Debenture" .

NanoViricides Down 5.4%, Shares Slide into the Red (NNVC)
Comtex SmarTrend(R) - Tue Jul 01, 12:44PM CDT
NanoViricides (NASDAQ:NNVC) is one of today's worst performing low-priced stocks, down 5.4% to $4.00 on 1.0x average daily volume. NanoViricides has traded 262,000 shares thus far today, vs. average volume of 256,000 shares per day. The stock has underperformed the Dow (-5.4% to the Dow's 1.0%) and underperformed the S&P 500 (-5.4% to the S&P's 0.9%) during today's trading.

Herpes Labialis (Oral Herpes) - Pipeline Review, H1 2014
M2 - Thu Jun 26, 4:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fp7wfj/herpes_labialis) has announced the addition of the "Herpes Labialis (Oral Herpes) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Herpes Labialis (Oral Herpes), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Herpes Labialis (Oral Herpes) and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Herpes Labialis (Oral Herpes) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Herpes Labialis (Oral Herpes) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Beech Tree Labs, Inc. - BioAlliance Pharma SA - Foamix Ltd. - NanoBio Corporation - NanoViricides, Inc. - Redox Pharmaceutical Corporation For more information visit http://www.researchandmarkets.com/research/fp...s_labialis

NanoViricides Reports That a Certificate of Occupancy Has Been Issued for the New cGMP Manufacturing and R&D Facility in Shelton, CT
Business Wire - Wed Jun 25, 6:00AM CDT
NanoViricides, Inc. (NYSE MKT:NNVC) (the "Company" reports that the Construction Phase for its total renovation program of the facility at 1 Controls Drive, Shelton, CT is now complete. The City of Shelton has issued a Certificate of Occupancy for this facility after inspection of the new facility. NanoViricides is now performing specific modifications for its custom equipment and utilities needs. Simultaneously, the facility validation process has also been started. The Company is in negotiations to purchase this facility rather than to lease it.




Scroll down for more posts ▼

Top 10 Most Recent News Articles

AdMaven's Mave AI: Revolutionizing Campaign Management

Updated Category News Views 106

Taking the Tedious Out of Advertising You've got to love it when technology actually makes life easier, rather than more complicated. AdMaven's latest fancy toy, the AI assistant Mave, is promising just that. It's designed to take the heavy lifting off advertisers' shoulders, especially the day-to-day grind of tweaking ad settings and monitoring performance. If you've...

Continue Reading
Loyalty Programs Cut $1500 Annually for Consumers

Updated Category News Views 56

Loyalty Programs: An Essential Tool for Households In a world where every dollar counts, retail loyalty programs have become more than just a marketing strategy—they're lifelines for American households scraping through each month. According to fresh research by the Retail Industry Leaders Association (RILA) and conducted by market research leader Circana, these...

Continue Reading
Midea's R290 Tech: Real Green Cooling Revolution?

Updated Category News Views 258

A Fresh Breeze in Sustainable Cooling In the middle of Kigali’s innovation oasis, Midea RAC stood out at MOP38, the 38th Meeting of the Parties to the Montreal Protocol, flexing its sustainable tech muscles. We're talking about their R290 air conditioning technology—a natural refrigerant with zero ozone footprint and a global warming potential of a mere three. This is...

Continue Reading
ROBOTERA Debuts XHAND 1 Pro-U in NVIDIA Demo

Updated Category News Views 145

ROBOTERA Steps Up with XHAND 1 Pro-U Move over, traditional robotics; ROBOTERA is here to shake things up with their latest marvel, the XHAND 1 Pro-U. This futuristic gadget isn't just making waves at the Conference on Robot Learning (CoRL) where Jim Fan of NVIDIA spotlighted it in his GR00T 2 demo, it's setting a new bar for robotic dexterity. Hand in Glove with Human...

Continue Reading
DarioHealth's New Research Tackles Healthcare Cost Estimation

Updated Category News Views 104

Unpacking Dario's Bold Surgical Strike at ISPOR Europe Alright, folks, DarioHealth is shaking up the stage with their new methodology that could very well carve a new path in how we size up digital healthcare savings. Presented at ISPOR Europe 2026, Dario's tactic bypasses the sluggish wait on medical claims data, instead offering an evidence-driven peek at potential...

Continue Reading
Alliance for Women in Media Champions Change in 2026

Updated Category News Views 60

A Celebration of Trailblazing Women in Media If there's one thing I've learned about strong leadership, it's that you can't fake authenticity. Today, we're tipping our hats to some genuine trailblazers. The Alliance for Women in Media (AWM) held its annual Gracies Leadership Awards, celebrating the achievements and vision of seven remarkable women. Honoring the...

Continue Reading
Lennar Faces Legal Heat Over Alleged Misleading Statements

Updated Category News Views 39

Rumbling Legal Drama with Lennar Corporation Every trader knows the uneasy feeling when a stock you're eyeing takes a surprising nosedive on some legal muck coming out of the woodwork. Well, it's Lennar Corporation's turn in the spotlight for all the wrong reasons. They're getting slapped with a class action lawsuit by investors claiming the company pulled a fast one...

Continue Reading
Caladan Partners with Anchorage for Stronger Trading

Updated Category News Views 50

Caladan and Anchorage Unite for Asset Growth Man, partnerships might just be the secret sauce we never know we need until it’s on our plate. It's a fresh day in digital trading, and Caladan just shook things up by teaming up with Anchorage Digital, bolstering their trading and settlement capabilities to satisfy the big players. If there's one thing that's hot as a...

Continue Reading
Thunes Boosts Bhutan Remittances with Instant Payments

Updated Category News Views 283

Thunes' Network Expands to Bhutan: A Game Changer I'll say one thing clear—Thunes isn't messing around. They've just opened the gates for real-time payouts to Bhutan, and it's going to be a game-changer for those living abroad who want to send money back home. Look, for years, Non-Resident Bhutanese have been diving into hoops just to get their bucks across borders....

Continue Reading
Dr. Obeng Joins WellcomeMD with Special Offer for Patients

Updated Category News Views 23

New Beginnings in Concierge Medicine In late October, WellcomeMD opened its doors to Dr. Paa-Kofi Obeng—an arrival greeted with considerable anticipation in Richmond's medical scene. This isn't just any run-of-the-mill staff addition; Dr. Obeng brings with him over a decade of experience from places like the Veterans Administration Medical Center. He's armed with a...

Continue Reading

Top 5 Most Recently Viewed Articles

Analysts Alter Predictions for Texas Instruments Earnings Release

Updated Category News Views 48

Analysts Update Forecasts for Texas Instruments Earnings Texas Instruments Incorporated (NASDAQ: TXN) is set to unveil its third-quarter earnings results, scheduled for release after the market closes on a Tuesday evening. Investors are keenly anticipating the outcome as industry buzz suggests that earnings could reflect a notable change from previous figures. Current...

Continue Reading
Iris Energy Limited: Understanding Investor Rights and Legal Options

Updated Category News Views 117

Understanding Your Rights as an Investor in Iris Energy Limited As an investor in Iris Energy Limited, it’s essential to know your rights, especially during challenging times. The legal landscape surrounding securities can be complex, and having informed legal support is crucial. Many investors are unaware of their options and the potential to recover losses stemming...

Continue Reading
McKesson Corporation Set to Release Earnings This November

Updated Category News Views 108

McKesson Corporation's Second Quarter Earnings Announcement McKesson Corporation (NYSE: MCK) is preparing to release its earnings report for the second quarter of fiscal 2025, which will happen after the market closes. Investors and stakeholders can expect to see the detailed financial results made public on a Wednesday. This announcement is a significant moment for the...

Continue Reading
Advantech's Innovations at Medical AI Solutions Conference

Updated Category News Views 122

Advantech Unveils Cutting-Edge Medical AI Solutions Advantech, a renowned global leader in industrial IoT and edge computing solutions, is excited to announce its presence at the MedTech Conference, an event that gathers leading figures in healthcare technology to discuss innovations shaping the future of patient care. Attendees will find Advantech at Booth #1007,...

Continue Reading
Canada's Defence Investment Spurs Innovation and Growth for Draganfly

Updated Category News Views 236

Canada's Defence Investment: A New Era for Technological Advancement In a bold effort to enhance national security, the Canadian government has revealed a significant long-term defence investment package worth $80 billion. This strategic move, championed by Prime Minister Mark Carney, is designed to advance technological capabilities in defence, bolster domestic...

Continue Reading